# 12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

> **NCT02586909** · PHASE3 · TERMINATED · sponsor: **Axovant Sciences Ltd.** · enrollment: 1099 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** RVT-101 35 mg tablets

## Key facts

- **NCT ID:** NCT02586909
- **Lead sponsor:** Axovant Sciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04-26
- **Primary completion:** 2018-03-12
- **Final completion:** 2018-03-12
- **Target enrollment:** 1099 (ACTUAL)
- **Why stopped:** Intepirdine did't meet primary efficacy endpoints in lead-in study RVT-101-3001
- **Last updated:** 2020-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586909, "12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02586909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*